TacticScaleWhat Viatris Does & How It Makes Money (VTRS)
Updated October 2026 · reflects Viatris's latest reported financials
Global maker of generic, branded, and biosimilar medicines. Viatris earns revenue by selling brand, generic, complex generic, and biosimilar medicines to wholesalers, distributors, pharmacies, payers, insurers, governments, and institutions.
How Viatris makes money
Viatris earns revenue by selling brand, generic, complex generic, and biosimilar medicines to wholesalers, distributors, pharmacies, payers, insurers, governments, and institutions. Sales are split across four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It also develops new products through partnerships with other drug companies.
What Viatris does
Viatris is a global healthcare company headquartered in Canonsburg, Pennsylvania, with roots going back to 1961. It sells a wide range of medicines, including prescription brand drugs, generics, complex generics, and biosimilars, in forms such as oral tablets, injectables, and complex dosage forms. Its brands include long-established names like Lipitor, Norvasc, Viagra, Zoloft, Xanax, Lyrica, and Celebrex, along with the EpiPen Auto-Injector and respiratory products such as Wixela Inhub, Breyna, and Yupelri. The company reports four segments: Developed Markets, Greater China, JANZ (Japan, Australia, and New Zealand), and Emerging Markets. It sells through wholesalers, retail, institutional, mail-order, e-commerce, and specialty pharmacies. Its pipeline work includes collaborations with Mapi Pharma on long-acting glatiramer acetate depot products, Revance Therapeutics on a proposed BOTOX biosimilar, and Theravance Biopharma on revefenacin.
Products & services
- Lipitor
- Viagra
- EpiPen Auto-Injector
- Lyrica
- Norvasc
- Wixela Inhub
What is Viatris worth?
On an owner-earnings DCF, Viatris's most-likely value is about $21 versus a recent price near $18 (20% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$16) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ High leverage — net debt is 6.7× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Vertex Pharmaceuticals (VRTX) · Pfizer (PFE) · Vir Biotechnology (VIR) · AbbVie (ABBV) · Veeva Systems (VEEV)